Ratings AbbVie Inc.

Equities

ABBV

US00287Y1091

Real-time Estimate Cboe BZX Other stock markets 01:17:53 2023-12-11 pm EST			5-day change	1st Jan Change
151.58 ^USD	+1.54%		+5.16%	-6.20%

02:22pm	Goldman Sachs Upgrades AbbVie to Buy From Neutral, Raises Price Target to $173 From $149	MT
02:05pm	AbbVie, Genmab Report Strong, Durable Response Among Lymphoma Patients Treated With Epcoritamab	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
According to Refinitiv, the company's ESG score for its industry is good.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The group shows a rather high level of debt in proportion to its EBITDA.
With a 2023 P/E ratio at 28.29 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector : Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ABBVIE INC.	-6.20%	264 B $	C+
ELI LILLY AND COMPANY	+58.17%	538 B $	C+
NOVO NORDISK A/S	+42.69%	430 B $	B
JOHNSON & JOHNSON	-12.45%	372 B $	C+
MERCK & CO., INC.	-5.88%	263 B $	B-
ROCHE HOLDING AG	-12.46%	232 B $	A+
NOVARTIS AG	+2.38%	198 B $	B-
PFIZER, INC.	-44.29%	163 B $	C+
AMGEN INC.	+3.48%	144 B $	C+
SANOFI	-2.27%	116 B $	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes